weight loss plateau glp 1 Blog Weight loss Plateau on GLP-1

Studies are demonstrating a plethora of positive effects on cardiovascular health, renal disease and liver disease, which may be directly related to the mitigation of the diabetes or obesity-associated risks of these complications or possibly direct protective effects

Using an Insulin Syringe

GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.

Several patterns appear consistently: Loss of lean muscle mass Inadequate protein intake Nutrient deficiencies, particularly vitamin D and magnesium This matters because muscle mass plays a direct role in supporting skeletal health

A retrospective cohort study found GLP-1R agonists were associated with lower risks of cardiovascular or psychiatric comorbidities, lower mortality among patients with psoriasis.

Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created both clinical and supply chain challenges.